Researchers in the Basic Sciences Division have, for the first time, induced a state of reversible metabolic hibernation in mice. This achievement, the first demonstration of "hibernation on demand" in a mammal, ultimately could lead to new ways to treat cancer and prevent injury and death from insufficient blood supply to organs and tissues.
"We are, in essence, temporarily converting mice from warm-blooded to cold-blooded creatures. This is exactly the same thing that happens naturally when mammals hibernate," said lead investigator Dr. Mark Roth, whose findings appear in the April 22 issue of Science. "We think this may be a latent ability that all mammals have — potentially even humans — and we're just harnessing it and turning it on and off, inducing a state of hibernation on demand."
During a hibernation-like state, cellular activity slows to a near standstill, which dramatically reduces an organism's need for oxygen. If such temporary metabolic inactivity — and subsequent freedom from oxygen dependence — could be replicated in humans, it could help buy time for critically ill patients on organ-transplant lists and in operating rooms, ERs and battlefields, Roth said. Clinical applications of induced metabolic hibernation could also include treating severe blood-loss injury, hypothermia, malignant fever, cardiac arrest and stroke.
"Manipulating this metabolic mechanism for clinical benefit potentially could revolutionize treatment for a host of human ills related to ischemia, or damage to living tissue from lack of oxygen," said Roth, also an affiliate professor of biochemistry at the University of Washington School of Medicine.
Collaborators on the research included first author Eric Blackstone, a graduate research assistant in Roth's laboratory and a member of the joint Fred Hutchinson/University of Washington Molecular and Cellular Biology Program; and co-author Dr. Mike Morrison, a staff scientist in Roth's lab.
Other potential medical benefits include improving cancer treatment by allowing patients to tolerate higher radiation doses without damaging healthy tissue. Cancer cells, Roth explained, aren't dependent on oxygen to grow. As a result, they are more resistant to radiation than surrounding healthy cells, which need oxygen to live. Roth hypothesizes that temporarily eliminating oxygen dependence in healthy cells could make them a less-vulnerable target for radiation and chemotherapy and thus spare normal tissue during high-dose cancer therapy.
"Right now in most forms of cancer treatment we're killing off the normal cells long before we're killing off the tumor cells. By inducing metabolic hibernation in healthy tissue we'd at least level the playing field," he said.
The delivery of such treatment could be as simple as an intravenous infusion of saline solution mixed with trace amounts of an agent that would interfere with the body's ability to use oxygen, Roth said.
Using oxygen deprivation to depress metabolic activity also might extend the amount of time doctors can preserve organs and tissues outside the body prior to transplantation, Roth said. Yet another potential application of oxygen deprivation would include accelerating wound healing in patients, such as diabetics, whose ability to do so is compromised. This could reduce the number of amputations caused by irreparable tissue damage from wounds that won't heal. A wound to the skin allows the entry of oxygen, which initiates cell death. In healthy people, cell death subsides when a clot forms, which allows the healing process to begin. Exposing a diabetic's clot-resistant wound to an oxygen-free environment would speed the healing process.
While the notion of putting a human or a human organ into an oxygen-free state of biological limbo and then reversing the process at will with no ill effects may sound like science fiction, dozens of documented cases exist of humans surviving prolonged hibernation-like states with no lingering physical or neurological damage. For example:
"Understanding the connections between random instances of seemingly miraculous, unexplained survival in so-called clinically dead humans and our ability to induce — and reverse — metabolic quiescence in model organisms could have dramatic implications for medical care," Roth said. "In the end, I suspect there will be clinical benefits and it will change the way medicine is practiced, because we will, in short, be able to buy patients time."
In the Science paper, Roth and colleagues report inducing a state of clinical torpor in mice for up to six hours before restoring their normal metabolic function and activity.
They achieved this by placing the mice in a chamber filled with normal room air laced with 80 parts per million of hydrogen sulfide, a chemical normally produced in humans and animals that is believed to help regulate body temperature and metabolic activity.
Within minutes of breathing the hydrogen sulfide and room-air cocktail, the mice stopped moving and appeared to lose consciousness, their respiration dropped from the normal 120 breaths per minute to fewer than 10 breaths per minute, and their core temperature dropped from the normal 37 degrees Celsius to as low as 11 C, depending on the controlled ambient temperature within the chamber.
"We have, on demand, reversibly demonstrated the widest range of metabolic flexibility that anyone has ever seen in a non-hibernating animal," Roth said.
"The cool thing about this gas we're using, hydrogen sulfide, is that it isn't something manufactured that we're taking down from a shelf — it isn't 'better living through chemistry' — it's simply an agent that all of us make in our bodies all the time to buffer our metabolic flexibility. It's what allows our core temperature to stay at 98.6 degrees, regardless of whether we're in Alaska or Tahiti," Roth said.
In addition to mice, Roth and colleagues in previously published work have demonstrated the ability to metabolically arrest — and subsequently re-animate — such model organisms as yeast and worms, as well as the embryos of fruit flies and zebrafish.
In each case they achieved metabolic suspension through oxygen deprivation caused by exposure to gases such as hydrogen sulfide and carbon monoxide. Known as oxygen mimetics, these chemicals are very similar to oxygen at the molecular level and so bind to many of the same receptor sites. As a result, they compete for and interfere with the body's ability to use oxygen for energy production — a process within the cell's power-generating machinery called oxidative phosphorylation. The inhibition of this function, in turn, is what the researchers believe causes the organism to shut down metabolically and enter a hibernation-like state. In each case, upon re-exposure to normal room air, the organisms quickly regained normal function and metabolic activity with no long-term negative effects.
If Roth and colleagues are able to replicate these findings in larger animal models, they foresee the first clinical use of this technology in humans could involve treating people suffering from severe fevers of unknown origin. Currently, when a person comes to an ER with such a fever they run the risk of brain-damaging seizures during the crucial time it takes to diagnose the bacterial or viral cause and administer the proper antibiotic.
"Here's a patient group, quite commonly found in emergency rooms around the country, who would do well if they could just have their core body temperature taken down in order to buy them time until the pathology reports come back and they can get on the right course of treatment," Roth said. "Today, physicians have no way of dealing with uncontrolled fever other than literally putting people on ice. Well, we believe we know how to flip the breaker on the patient's furnace; if they have a fever, we believe we know how to stop it on a dime." Roth anticipates that such clinical trials in humans could be under way within about five years.
Biotech company will develop commercial applications for reversible metabolic control technology
On the heels of his landmark discovery, Dr. Mark Roth, Basic Sciences Division investigator, and co-founders Fred Hutchinson and ARCH Venture Partners announced the birth of Ikaria, Inc. The new biotechnology company will advance Roth's continuing research in inducing reversible metabolic hibernation in animals and, eventually, humans.
A healing name
Named after a Greek island known for therapeutic hot springs, Ikaria will develop and commercialize the technology and resulting products for the treatment of high-risk, critically ill patients.
The company has received a substantial investment from ARCH Venture Partners, Venrock Associates, 5AM Ventures, Aravis Ventures and the Washington Research Foundation, some of the country's leading early stage life-science investors.
Ikaria's board of directors features experts with deep experience in launching and sustaining new biotechnology companies. In addition to Roth, the board includes chairman Vaughn Kailian, managing partner of Deerhaven Partners, board chairman of ViaCell and Elixir Pharmaceuticals and formerly with COR Therapeutics and Millennium (MLNM).
"Dr. Roth has developed exciting technology with a significant potential to advance the field of medicine and the treatment of patients," Kailian said. "We look forward to seeing this new technology through development and into clinical practice where we believe it will yield great benefits."
Roth's research was inspired by well-documented cases of people who have survived long periods of time in extreme cold. In such cases the metabolism slows to a negligible rate as a form of protection against the elements. Roth has been researching metabolic control for 16 years.
Early funding for the research came from Fred Hutchinson, which has also obtained for the new company an exclusive worldwide license for the technology. The National Institutes of Health and the Department of Defense, which is seeking new ways to extend the time available to treat military personnel with battlefield wounds, also contributed funding.
The board has recruited Dr. Kevin Tomaselli as its chief technology officer. Ikaria also has initiated aworldwide search for a chief executive officer. For information about Ikaria, visit www.ikariainc.com.